


# Are There Significant Differences in 12-Month FVC Decline Between Pirfenidone and Nintedanib?

## STUDY DESIGN

Post hoc analysis of CleanUP-IPF trial comparing patients with idiopathic pulmonary fibrosis (IPF)

Compared outcomes of patients receiving pirfenidone and those receiving nintedanib

## RESULTS



### 12 MONTHS:

**Nintedanib** had a higher FVC, mean difference of 106 mL (95% CI, 34-178;  $P = .004$ )

### 24 MONTHS:

FVCs not different

No difference in survival or hospitalization

Patients with IPF who used nintedanib had a slower 12-month FVC decline than those who used pirfenidone in a post hoc analysis of the CleanUP-IPF trial.